We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Redhill Biopharma Ltd | NASDAQ:RDHL | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0377 | 8.74% | 0.469 | 0.4352 | 0.469 | 0.4634 | 0.437 | 0.4376 | 230,099 | 00:50:01 |
Perry Wildes, Adv.
Gross & Co.
One Azrieli Center
Tel Aviv 6702100, Israel
+972 (3) 607-4444
|
Rick A. Werner, Esq.
Haynes and Boone, LLP
30 Rockefeller Plaza
New York, New York 10112 (212) 659-7300 |
Transaction Valuation(1)
|
Amount of Filing Fee(2)
|
$9,855,654
|
$1,075.25
|
1
|
Estimated solely for purposes of calculating the amount of the filing fee. The calculation of the Transaction Valuation assumes that all the outstanding options to purchase American Depositary Shares, each
representing ten ordinary shares of the Issuer, par value NIS 0.01 per ordinary share (“ADSs”), that may be eligible for exchange in the offer will be tendered pursuant to this
offer. This calculation assumes options to purchase an aggregate of 2,805,281 ADSs, having an aggregate value of $9,855,654 as of April 23, 2021, calculated based on the average of values using the binomial option pricing model, will be
exchanged pursuant to this offer.
|
2
|
The amount of the filing fee, calculated in accordance with Rule 0-11(b) of the Securities Exchange Act of 1934, as amended, equals $109.10 per $1,000,000 of the aggregate amount of the Transaction Valuation
(or 0.01091% of the aggregate Transaction Valuation). The Transaction Valuation set forth above was calculated for the sole purpose of determining the filing fee and should not be used for any other purpose.
|
☐
|
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
|
Amount Previously Paid:
|
|
Not applicable
|
|
Filing Party:
|
|
Not applicable
|
Form or Registration No.:
|
|
Not applicable
|
|
Date Filed:
|
|
Not applicable
|
☐
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
|
☐
|
third party tender offer subject to Rule 14d-1.
|
|
☒
|
Issuer tender offer subject to Rule 13e-4.
|
|
☐
|
going-private transaction subject to Rule 13e-3.
|
|
☐
|
amendment to Schedule 13D under Rule 13d-2.
|
|
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
|
|
☐
|
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
|
☐
|
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
|
Executive Officers
|
|
Title
|
Dror Ben-Asher
|
|
Chief Executive Officer and Chairman of the Board of Directors
|
Micha Ben Chorin
|
|
Chief Financial Officer
|
Reza Fathi, Ph.D.
|
|
Senior Vice President Research and Development
|
Gilead Raday
|
Chief Operating Officer
|
|
Adi Frish
|
Chief Corporate & Business Development Officer
|
|
Guy Goldberg
|
Chief Business Officer
|
|
Rick D. Scruggs
|
Chief Commercial Officer and Director
|
|
Dr. June Almenoff
|
Chief Scientific Officer
|
|
Directors
|
|
|
Shmuel Cabilly, Ph.D.
|
|
Director
|
Eric Swenden
|
|
Director
|
Kenneth Reed, Ph.D.
|
|
Director
|
Ofer Tsimchi
|
|
Director
|
Alla Felder
|
|
Director
|
Alessandro Della Chà
|
Director
|
|
(1)
|
The information set forth under Section 9 (“Interests of Directors and Executive Officers; Transactions and Arrangements Concerning Our Securities”) of the Offering
Memorandum is incorporated herein by reference.
|
|
(2)
|
The information set forth under Section 11 (“Legal Matters; Regulatory Approvals”) of the Offering Memorandum is incorporated herein by reference.
|
|
(3)
|
Not applicable.
|
|
(4)
|
Not applicable.
|
|
(5)
|
Not applicable.
|
Exhibit
Number
|
|
Description
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
(b)
|
|
Not applicable
|
|
||
|
||
(g)
|
|
Not applicable
|
(h)
|
|
Not applicable
|
Date: April 26, 2021
|
REDHILL BIOPHARMA LTD.
|
||
By:
|
/s/ Dror Ben-Asher
|
||
Dror Ben-Asher
|
|||
Chief Executive Officer and
Chairman of the Board of Directors
|
1 Year Redhill Biopharma Chart |
1 Month Redhill Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions